Optimi Health Corp. (OPTI.CN)
| Previous close | 0.4400 |
| Open | 0.4400 |
| Bid | 0.4150 x N/A |
| Ask | 0.4300 x N/A |
| Day's range | 0.4200 - 0.4400 |
| 52-week range | 0.1500 - 0.5800 |
| Volume | |
| Avg. volume | 94,875 |
| Market cap | 39.144M |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Optimi Health Announces Closing of Fully Subscribed $1,500,000 Financing
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce it has closed a third and final tranche of its non-brokered private placement (the "Offering"). The Offering consisted of units (each a "Unit") at CAD$0.30 per Unit for gross proceeds of CDN$1,500,000. Optimi raised CDN$544,990 in the third tranche closed May 29,
- GlobeNewswire
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
Company preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber SchemeVANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as psilocybin and MDMA, is pleased to announce that it has received an import permit from Mind Medicine Australia (MMA) to export its GMP MDMA and psi
- GlobeNewswire
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
VANCOUVER, British Columbia, May 22, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, has entered a Letter of Intent (LOI) with ATMA Journey Centers (ATMA). ATMA is a pioneering Canadian firm focused on advancing innovative solutions in psychedelic-assisted therapy. The LOI outlines Optimi's commitment to supply
